ME3183 (also known as Morcamilast or PDE4‑IN‑14) is an oral, highly selective phosphodiesterase‑4 (PDE4) inhibitor developed by Meiji Seika Pharma, currently investigated for moderate-to-severe plaque psoriasis, with potential applicability in inflammatory dermatological conditions like atopic dermatitis. The directory classifies it as a preclinical API with a synthetic source/manufacturing origin. Other names for this substance include orb1944210 and CS-0887718. Its PubChem CID is 142395866.
Pde4-IN-14
| CAS No | 2231329-25-0 |
|---|---|
| Molecular Formula | C19H20F2N4O3S |
| Molecular Weight | 422.5 g/mol |
| Synonyms | 1-[[2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(1,3-thiazol-2-yl)-1,3-benzoxazol-4-yl]oxy]-1,1-difluoro-2-methylpropan-2-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
ME3183 (also known as Morcamilast or PDE4‑IN‑14) is an oral, highly selective phosphodiesterase‑4 (PDE4) inhibitor developed by Meiji Seika Pharma, currently investigated for moderate-to-severe plaque psoriasis, with potential applicability in inflammatory dermatological conditions like atopic dermatitis.
The listed CAS number is 2231329-25-0.
The listed molecular formula is C19H20F2N4O3S.
The listed molecular weight is 422.5 g/mol.
1-[[2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(1,3-thiazol-2-yl)-1,3-benzoxazol-4-yl]oxy]-1,1-difluoro-2-methylpropan-2-ol.
The source lists orb1944210 and CS-0887718.